Family burden in inherited ichthyosis: creation of a specific questionnaire

Orphanet Journal of Rare Diseases

Charles Taïeb⁴  Christine Bodemer²  Vincent Sibaud¹  Cécile Méni³  Smail Hadj-Rabia²  Hélène Dufresne³ 

[1] Eau Thermale Avène, Lavaur, France;Université Paris V-Descartes, Paris, France;Department of Dermatology, Necker-Enfants Malades Hospital, Centre de Référence National pour les Maladies Génétiques à Expression Cutanée (MAGEC), APHP, Paris, France;Public Health and Quality of Life, Pierre Fabre, Boulogne, France

关键词: Burden questionnaire;    Ichthyosis;    Quality of life;    Global burden disease;   

Others  :  864117
DOI  :  10.1186/1750-1172-8-28

 received in 2012-11-22, accepted in 2013-02-03,  发布年份 2013

【 摘 要 】

Background

The concept of individual burden, associated with disease, has been introduced recently to determine the “disability” caused by the pathology in the broadest sense of the word (psychological, social, economic, physical). Inherited ichthyosis belong to a large heterogeneous group of Mendelian Disorders of Cornification. Skin symptoms have a major impact on patients’ Quality of Life but little is known about the burden of the disease on the families of patients.

Objectives

To develop and validate a specific burden questionnaire for the families of patients affected by ichthyosis.

Methods

Two steps were required. First, the creation of the questionnaire which followed a strict methodological process involving a multidisciplinary team and families. Secondarily, the validation of the questionnaire, including the assessment of its reliability, external validity, reproducibility and sensitivity, was carried out on a population of patients affected by autosomal recessive congenital ichthyosis. A population of parents of patients affected by ichthyosis was enrolled to answer the new questionnaire in association with the Short Form Q12 questionnaire (SF-12) and a clinical severity score was filled for each patient.

Results

Ninety four families were interviewed to construct the verbatim in order to create the questionnaire and a cognitive debriefing was realized. The concept of burden could be structured around five components: “economic”, “daily life”, “familial and personal relationship”, “work”, and “psychological impact”. As a result, “Family Burden Ichthyosis” (FBI) reproducible questionnaire of 25 items was created.

Forty two questionnaires were analyzable for psychometric validation. Reliability (Cronbach’s alpha coefficient = 0.89), reflected the good homogeneity of the questionnaire. The correlation between mental dimensions of the SF-12 and the FBI questionnaire was statistically significant which confirmed the external validity. The mean FBI score was 71.7 ± 18.8 and a significant difference in the FBI score was shown between two groups of severity underlining a good sensitivity of the questionnaire.

Conclusions

The internal and external validity of the “FBI” questionnaire was confirmed and it is correlated to the severity of ichtyosis. Ichthyoses, and other chronic pathologies, are difficult to assess by clinical or Quality of Life aspects alone as their impact can be multidimensional. “FBI” takes them all into consideration in order to explain every angle of the handicap generated.

【 授权许可】

   
2013 Dufresne et al; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Oji V, Tadini G, Akiyama M: Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Sorèze 2009. J Am Acad Dermatol 2010, 63:607-641.
• [2]Di Giovanna JJ, Robinson-Bostom L: Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 2003, 4:81-95.
• [3]Gånemo A, Sjöden PO, Johansson E: Health-related quality of life among patients with ichthyosis. Eur J Dermatol 2004, 14:61-66.
• [4]Oji V, Traupe H: Ichthyosis, clinical manifestations and practical treatment options. Am J Clin Dermatol 2009, 10:351-364.
• [5]Bodemer C, Bourrat E, Mazereeuw-Hautier J: Short- and medium-term efficacy of specific hydrotherapy in inherited ichthyosis. Br J Dermatol 2011, 165:1087-1094.
• [6]Gånemo A, Virtanen M, Vahlquist A: Improved topical treatment of lamellar ichthyosis: a double-blind study of four different cream formulation. Br J Dermatol 1999, 141:1027-1032.
• [7]Verfaille CJ, Vanhoutte FP, Blanchet-Bardon C: Oral liazorazole vs. Acitretin in the treatment of ichthyosis: a phase II/III multicentre, double-blind, randomized, active-controlled study. Br J Dermatol 2007, 156:965-973.
• [8]Steijlen PM, Van Dooren-Greebe RJ, Van de Kerkhof PC: Acitretin in the treatment of lamellar ichthyosis. Br J Dermatol 1994, 130:211-214.
• [9]Lacour M, Mehta-Nikhar B, Atherton DJ: An appraisal of acitretin therapy in children with inherited disorders of keratinisation. Br J Dermatol 1996, 134:1023-1029.
• [10]Kamalpour L, Gammon B, Chen KH: Resource utilization and quality of life associated with congenital ichthyoses. Pediatr Dermatol 2011, 28:512-518.
• [11]Gånemo A, Lindholm C, Lindberg M: Quality of life in adults with congenital ichthyosis. J Adv Nurs 2003, 44:412-419.
• [12]Mazereeuw-Hautier J, Dreyfus I, Barbarot S: Factors influencing quality of life of inherited ichthyosis: a qualitative study in adult using focus group. Br J Dermatol 2012, 166:646-648.
• [13]World Health Organization: About the Global Burden of Disease (GBD) project [WWW document]. 2010. URL [http://www.who.int/healthinfo/global_burden_disease/about/en/ webcite]
• [14]Guex JJ, Rahhali N, Taïeb C: The patient’s burden of chronic venous disorders: construction of a questionnaire. Phlebology 2010, 25:280-285.
• [15]Meyer N, Paul C, Feneron D: Psoriasis: an epidemiological evaluation of disease burden in 590 patients. J Eur Acad Dermatol Venereol 2010, 24:1075-1082.
• [16]Serra E, Spaeth M, Carbonell J: Development of the fibromyalgia burden assessment: measuring the burden of fibromyalgia multifaceted. Clin Exp Rheumatol 2010, 28(Suppl 63):S87-S93.
• [17]Seidenberg M, Haltiner A, Taylor MA: Development and validation of a multiple ability self-report questionnaire. J Clin Exp Neuropsychol 1994, 16:93-103.
• [18]Whalley D, McKenna SP, Dewar AL: A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD). Br J Dermatol 2004, 150:274-283.
• [19]Smidt AC, Lai JS, Cella D: Development and validation of Skindex-Teen, a quality-of-life instrument for adolescents with skin disease. Arch Dermatol 2010, 146:865-869.
• [20]Wild D, Grove A, Martin M: ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005, 8:94-104.
• [21]Falissard B: Comprendre et utiliser les statistiques dans les sciences de la vie. 2nd edition. Paris: Masson; 2005:68. [Abrégés]
• [22]Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 1996, 34:220-233.
• [23]Collège des économistes de la santé: Guide méthodologique pour l’évaluation économique des stratégies de santé. 2003, 31-32. [http://www.ces-asso.org/docs/Guide_Methodologique_CES_2003 webcite]
• [24]Wild D, Grove A, Martin M, Eremenco S, McElroy S, Verjee-Lorenz A, Erikson P: ISPOR Task Force for Translation and Cultural Adaptation. Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation. Value Health 2005, 8:94-104.
• [25]Styperek AR, Rice ZP, Kamalpour L: Annual direct and indirect health costs of the congenital ichthyoses. Pediatr Dermatol 2010, 27:325-336.
• [26]Taieb C, Sibaud V, Merial-Kieny C: Impact of Avene hydrotherapy on the quality of life of atopic and psoriatic patients. J Eur Acad Dermatol Venereol 2011, 25(Suppl 1):24-29.